irbesartan in hypertension

Conditions: Hypertension

Summary: study objectives: * to demonstrate the effect of irbesartan on the regulation of diastolic blood pressure, in case of missing one dose after a period of administration for 6 to 8 weeks * to evaluate the safety of irbesartan


Eligibility criteria:
inclusion criteria: * having an average value of ≥ 95 mmhg and ≤ 109 mmhg in diastolic blood pressure measurement or an average diastolic blood pressure value of ≥ 85 mmhg in 24-hours arterial blood pressure measurement, * received no treatment within the last 3 months. exclusion criteria: * premenopausal women having at least one of the following conditions, * not surgically sterile, * are nursing, * having childbearing potential and not using a reasonable contraception method or not thinking to continue the method throughout the study. reasonable contraception methods are: intrauterine device, oral or implantable or injectable contraception methods. no methods other than these are accepted. * patients routinely sleeping within the day since she/he works at nightshift and whose working hours continue in a time shift from midnight to 04:00 a.m. * patients with average systolic blood pressure = 180 mmhg in sitting position or average diastolic blood pressure is ≥110 mmhg in sitting position at baseline visit * having known or suspected secondary hypertension * having renal and/or hepatic failure together with the following laboratory criteria: * having elevated values of sgpt (alt) or sgot (alt) (at least twice the upper limit of normal range) * having serum creatinine levels of \> 2.3 mg/dl (or \> 203 μmol/l) * with bilateral renal artery stenosis or single kidney and unilateral renal artery stenosis or those in post-renal transplantation or with single kidney, * having symptomatic sodium insufficiency, hypokalemia or hyperkalemia, * with volume deficiency, * with primary hyperaldosteronism, * with biliary obstructive disorders, * having congestive heart failure (new york heart association (nyha)-functional class chf iii-iv), * with unstable angina pectoris occurring within 3 months before he or she signed the informed consent. * with stroke occurring within 6 months before he or she signed the informed consent, * with myocardial infarction or having cardiac surgery within three months before he or she signed the informed consent, * underwent ptca (percutaneous transluminal coronary revascularization) within three months before he or she signed the informed consent, * having continuous tachycardia, atrial fibrillation, atrial flutter or other clinical arrythmias defined by the investigator * with hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically related aortic or mitral valve stenosis, * with insulin-dependant diabetes mellitus whose blood sugar regulation could not be controlled within the last 3 months after a hba1c measurement in which it is equal to 10%. * with a history of drug or alcohol addiction within the last 6 months before she or he signed the informed consent, * receiving a drug other than those defined in protocol for blood pressure regulation, * who have been participated in any investigational study within the prior month before she or he signed the informed consent * with a known hypersensitivity against any drug which will be used. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.